Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-28
2006-03-28
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07019000
ABSTRACT:
The invention provides agents and compounds (see (I) and (II)) for use in the treatment or prophylaxis of disease conditions caused or exacerbated by mammalian papillomaviruses, such as human papillomaviruses, as well as methods for the treatment or prevention thereof. In said formulae, R1–R4and n are as defined herein.
REFERENCES:
patent: 562750 (1993-09-01), None
patent: WO 96/09406 (1996-03-01), None
Sherman et al., Virology 237: 296-306, 1997.
Chen et al., Science 269: 529-531, 1995.
Tong et al., Proc. Natl. Acad. Sci. USA 94: 4412-4417, 1997.
Sedman et al., J. Virol. 65: 4860-4866, 1991.
Lamberti et al., EMBO J. 9: 1907-1913, 1990.
Etscheid et al., Virology 205: 583-585, 1994.
Klingelhutz et al., Nature 380: 79-82, 1996.
Myers and Androphy, The E6 protein, pp III-47-III-57, 1995.
Grossman et al., Oncogene 4: 1089-1093, 1989.
Kanada et al., Virology 185: 536-543, 1991.
Dsouza et al., Trends in Genetics 13: 497-498, 1997.
Chan et al., Virol. 69: 3074-3083, 1995.
Myers et al., Human papillomaviruses, pp II-E6-1-II-E6-7, 1994.
van Ranst et al., J. Gen. Virol. 73: 2653-2660, 1992.
Crook et al., Cell 67: 547-556, 1991.
Dala et al., J. Virol. 70: 683-688, 1996.
Nakagawa et al., Virology 212: 535-542, 1995.
Vousden et al., J. Virol. 63: 2650-2656, 1989.
Bartsch et al., EMBO J. 11: 2283-2291, 1992.
Bosch et al., J. Virology 64: 4743-4754, 1990.
Tummino et al., Proc. Natl. Acad. Sci. USA 93: 969-973, 1996.
Rice et al., J. Medicinal Cham. 39: 3606-3616, 1996.
Rice et al., Science 270: 1194-1197, 1995.
Huibregtse et al., Mol. Cell Biol. 13: 775-784, 1993.
Polyak et al., Nature 389: 300-305, 1997.
Scheffner et al., Proc. Natl. Acad. Sci. USA 91: 8797-8801, 1994.
White et al., Genes Dev. 8: 666-677, 1994.
Tan et al., Cancer Res 55: 4599-4605, 1995.
Beerheide et al., J. Natl. Cancer Inst. 91: 1211-1220, 1999.
Beerheide et al., Bioorganic and Medicinal Chemistry 8: 2549-2560, 2000.
Schifmann, Journal of the National Cancer Institute 87: 1345-1347, 1995.
Edmonds and Vousden, Journal of Virology 63: 2650-2656, 1989.
International Agency for Research on Cancer, IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 64: Human papillomaviruses, 1995, IARC, Lyon, France.
Frederickson et al., J. Neurosci. Meth. 20: 91-103, 1987.
Lehman et al., Carcinogenesis 14: 833-839, 1993.
von Knebel et al., Int. J. Cancer 52: 831-834, 1992.
Derwent Abstract Accession No: 92-303542/37, B05, JP 4-208223, Jul. 27, 1992, Kawaguchi Kagaku Kogyo KK).
Synlett, Aug. 1990, Katritzky, Alan R. et al., “The Synthesis of Bis(N,N-disubstituted amino) Trisulphides”.
Derwent Abstract Accession No: 95-340184/44, B05, JP 7-233057 A, Kinki Daigaku GH, Sep. 5, 1995.
Brain Research vol. 44, No.: 2 (1972), Lycke, E. et al., “The Monoamine Metabolism in Virol Encephalitides of the Mouse II, Turnover of Monoamines in Mice Infected with Herpes Simplex Virus”.
Derwent Abstract Accession No: 86-282536/43, B03, C02, JP 1207376A, Toyo Soda Mfg. KK, Sep. 13, 1986.
Derwent Abstract Accession No: 88-245781/35 A12, JP 3-178148 A, Nippon Oil Seal Ind, Jul. 22, 1988.
Derwent Abstract Accession No: 91-038784/05, S03, JP 2-304346 A, Nihon Parkerizing, Dec. 18, 1990.
Derwent Abstract Accession No: 91-122584/17, B03, JP 3-063258 A, Kuraray KK, Mar. 19, 1991.
Virology vol. 243, pp. 287-292, 1998, Ott, David E. et al., “Inhibition of Friend Virus Replication by a Compound that Reacts with the Nucleocapsid Zinc Finger: Anti-retroviral Effect Demonstrated in Vivo”, abstract: fourth, fifth, tenth and twelfth compounds of Table 1.
Journal of Medicinal Chemistry, vol. 40, No: 13 (1997) pp. 1969-1976, McDonnell, Nazli, B. et al., “Zinc Ejection as a New Rationale for the Use of Cystamine and Related Disulfide-containing Antiviral Agents in the Treatment of AIDS”, abstract; figures 1, 2; Table 1; p. 1973 last paragraph to p. 1974 first paragraph.
Techniques in Protein Chemistry VIII (Symp Protein Soc), 10th(1997), Meeting Date 1996, pp. 231-244, Chertova, E. et al., “Reaction of HSV-1 NC p7, Zinc Fingers with Electrophilic Reagents”, pp. 231-232, 235-237, 241-242.
Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 24, No: 12 (1996), pp. 1395-1400 (Hathout, Yetrib et al.), “Characterisation of Intermediates in the Oxidation of Zinc Fingers in Human Immunodeficiency Virus Type I Nucleocapsid Protein P7”, abstract, figure 1, p. 1397, column I, second paragraph, p. 1398, column 2, second paragraph.
Journal of Medicinal Chemistry, vol. 39, No: 19 (1996) pp. 3606-3616 (Rice, William G. et al), “Evaluation of Selected Chemotypes in Coupled Cellular and Molecular Target-Based Screens Identifies Novel HIV-I Zinc Finger Inhibitors”, abstract, p. 3608 column 2 last paragraph, Table 10.
Journal of Virology, vol. 70, No: 8 (1990) pp. 4966-4972 (Rein, Alan et al.), “Inactivation of Murine Leukemia Virus by Compounds that React with the Zinc Finger in the Viral Nucleocapsid Protein”, abstract, p. 4970 first paragraph.
Carcinogenesis, vol. 9, No: 9 (1988) pp. 1547-1551 (Rotstein, Joel B. et al), “Effect of Exogenous Glutathione on Tumour Progression in the Murine Skin Multistage Carcinogenesis Model”, abstract, p. 1547 last paragraph to p. 1548 first paragraph, p. 1549 first paragraph, figure 2.
Chemical Abstracts 102:8009 Rubber Chem Technol (1984), vol. 57 No: 4 pp. 744-754 RN 86796-75-0, 86796-78-3, 86796-79-4.
Chemical Abstracts 111:146042 Chromatographia (1989) vol. 27 No: 3-4 pp. 113-117.
Chemical Abstracts; RN 95255-69-9.
Chemical Abstracts; RN 103-34-4.
Beerheide Walter
Bernard Hans-Ulrich
Sim Mui Mui
Tan Yee Joo
Ting Anthony Eugene
Bacon & Thomas
Institute of Molecular & Cell Biology
Kwon Brian-Ying S.
Low Christopher S. F.
LandOfFree
Method of treating a disease condition caused or exacerbated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a disease condition caused or exacerbated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a disease condition caused or exacerbated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530270